APx Acquisition announces merger with OmnigenicsAI and MultiplAI Health
In a landmark transaction for the biotechnology and AI industries, APx Acquisition Corp. I (NASDAQ: APXI), OmnigenicsAI Corp, and MultiplAI Health Ltd have signed a definitive Business Combination Agreement (BCA). This deal, valued at approximately $340 million, is poised to create a leading global genomics company driven by artificial intelligence (AI), enhancing precision medicine through […]